Biotech

All Articles

Lykos 'disappointments' certainly not making known study transgressions with publisher

.Psychopharmacology has drawn three write-ups regarding midstage scientific test data determining Ly...

Analysts dig into Avidity's DMD gain, revealing subtleties in information

.Avidity Biosciences pleased real estate investors with stage 1/2 information in Duchenne muscular d...

Actinogen's cortisol blocker fails period 2 anxiety study

.Actinogen Medical's cortisol blocker has overlooked the primary endpoint of a period 2 research stu...

Bivictrix determines going personal only way to take ADC in to facility

.Antibody-drug conjugates (ADCs) have gone to the facility of several a billion-dollar biobuck licen...

TPG bests up funds to $580M for financial investments throughout life scientific researches

.Asset manager TPG, which has assisted biotechs including Sionna Rehabs and Santa Ana Bio, has excee...

Merck ceases stage 3 TIGIT trial in lung cancer cells for futility

.Merck &amp Co.'s TIGIT program has gone through one more setback. Months after shuttering a period ...

After a difficult year, Exscientia folds into Recursion

.After a year determined through pipe hairstyles, the shift of its own chief executive officer and a...

Cullinan, after $25M bargain, restore bispecific to Harbour

.Cullinan Therapy was blown away enough with Port BioMed's bispecific invulnerable activator that it...

A nearer examine Fierce Biotech's Fierce 15

.In this full week's incident of "The Best Line," our experts're diving into Strong Biotech's annual...

Lilly experiences period 2 failing of tau-targeting med

.The confetti is still flying from Eli Lilly's event commemorating the approval of Alzheimer's condi...